Skip to main content

Pharma firm plans to import Covid-19 treatment drug from Bangladesh

KARACHI: A local pharmaceutical company plans to import a generic version of remdesivir — a broad spectrum antiviral medication that has shown to reduce recovery time in Covid-19 patients — from a Bangladesh-based manufacturer.

The drug has been granted emergency use authorisation by the US Food and Drug Administration (FDA) and authorities in Japan and the UK to treat hospitalised patients with severe manifestations of coronavirus.

According to a statement released by Searle Company Limited on Friday, the firm has entered into an exclusive licensing and marketing agreement with Beximco Pharmaceuticals, Bangladesh.

“It’s the first company in the world to introduce the generic variant of the drug. Our partnership will provide an immediate supply of the finished product at an affordable price and will help healthcare providers of Pakistan to treat their hospitalised Covid-19 patients without any delay,” said Mohammad Sajid, business development director at Searle.

Company asks authorities for urgent regulatory approval

The company decided not to make any commercial profit from the import (till the time the pandemic is over) and also to donate it to the government and Covid-19-designated hospitals, he added.

Asked about drug price in Bangladesh and its dosage, Mr Sajid said it cost around $70 per vial and six to a dozen vials were administered to a patient depending upon disease’s severity.

“Remdesivir is a direct-acting viral drug that inhibits viral RNA (Ribonucleic acid) synthesis. It is administrated intravenously and is authorized for the treatment of hospitalized patients with severe Covid-19 infection.”

Searle, he said, was actively taking the matter to the relevant authorities of Pakistan for necessary regulatory approval and was confident that in the existing pandemic, the relevant authorities would consider the matter on an urgent basis to support the product availability.

“Meanwhile, the drug would be imported under the patient access programme, which allows import when hospitals make a demand.”

Bangladesh, according to experts, has made remarkable progress in the pharmaceutical sector in recent years.

Some Bangladesh-based pharmaceutical companies, they said, were approved by the FDA and exported their products to the US. The global trade rules allow nations defined by the United Nations as least-developed countries (LDCs) to manufacturer patented drugs to make them more affordable in their markets. Bangladesh is one of 47 countries that fall in this category while Pakistan is not.

Remdesivir is currently undergoing clinical trials around the world, including in the UK. Early data suggests it can cut recovery time by about four days, but so far there has been no evidence that it will save more lives.

Earlier this month, Ferozsons Laboratories Limited, a subsidiary of BF Biosciences Ltd, said it would make the drug in Pakistan after signing a non-exclusive licensing pact with the US-based Gilead, which manufactured the drug, to make and sell the drug to 127 nations. However, the pharmaceutical company had announced that its production could take weeks.

Published in Dawn, May 30th, 2020



from The Dawn News - Home https://ift.tt/2AiH1wC
via IFTTT

Comments

Popular posts from this blog

IT ministry forms panel to review social media rules

ISLAMABAD: While uproar against the new rules to regulate social media continues from various segments of society, including parliamentarians, the Pakistan Federal Union of Journalists (PFUJ) and civil society, the information technology ministry on Friday formed a committee to review the rules. The federal cabinet approved the rules on Feb 11, but later after opposition from various quarters, including companies that manage different social media platforms, the prime minister announced that a fresh consultation process would be launched over the Citizens Protection (Against Online Harm) Rules 2020. The committee formed by the IT ministry is headed by Pakistan Telecommunication Authority Chairman Amir Azeem Bajwa while its members are Eazaz Aslam Dar, additional secretary of IT; Tania Aidrus, member of the Strategic Reforms Imple­mentation Unit, Prime Minister Office; and Dr Arslan Khalid, focal person on digital media at the PM Office. Federal Minister for Human Rights Dr Shireen Ma

Young girl’s tragic story makes her symbol of Yemen war

Buthaina Mansur al-Rimi’s life has changed drastically since last year — orphaned in Sanaa, the little girl controversially ended up in Saudi Arabia for medical care and has just returned to Yemen’s capital. Her entire immediate family was wiped out in an air strike by a Saudi-led coalition that backs Yemen’s government, using an explosive device Amnesty International says was made in the US. Images of Buthaina’s rescue and a picture of her swollen and bruised at a hospital trying to force open one of her eyes with her fingers were beamed worldwide. That international fame saw her become something of a propaganda pawn in the war between Yemen’s Iran-backed Huthi rebels and Saudi media. “I was in my mother’s room with my father, sisters, brother and uncle, the first missile hit, and my father went to get us sugar to get over the shock, but then the second missile hit, and then the third,” she says. “And then the house fell,” adds the little girl, who says she is eight. It was the